BACKGROUND: Non-alcoholic steatohepatitis (NASH) is an inflammatory subtype of non-alcoholic fatty liver disease (NAFLD) and recent non-invasive test, MACK-3, demonstrated good diagnostic characteristics for fibrosis in several studies. The aim of our study was to assess the liver state using the non-invasive MACK-3 Test, and its link with liver fibrosis stage, inflammatory activity, steatosis, and metabolic markers in NAFLD patients with hypertension (HT).
METHODS: Thirty adult NAFLD patients with HT, aged 30 to 60 years (mean age 46.36±5.1 years) were included in our study. The control group consisted of 20 healthy volunteers. In addition to basic laboratory tests and ultrasonographic examination, validated non-invasive fibrosis test were performed. MACK-3 was calculated using the online calculator with the following variables: fasting glucose, fasting insulin, aspartate aminotransferase (AST) and cytokeratin 18 (CK18).
RESULTS: All NAFLD patients with HT were characterized with increased liver enzymatic activity, lipid profile, increased levels of insulin and HOMA-IR˂0.001. MACK-3 parameters were positively correlated with thymol test = 0.45 (P<0.013), with aspartataminotransferase (AST) = 0.38 (P<0.03) and alanineaminotransferase (ALT) - =0.38 (P<0.03), with the stage of Fibrotest activity = 0.25 (P<0.018) and steatosis = 0.76 (P<0.001).
CONCLUSIONS: MACK-3 parameters associations with hepatic enzymatic activity, steatosis and activity stage suggest this test as a promising for screening use in such patients and requires further studies.
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.